S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

PDSB PDS Biotechnology Corporation

3.35

-0.04 (-1.18%)

After Hours

Last Updated: 07:00:16

Delayed by 15 minutes

PDS Biotech shares gain 12% after PDS0101 triple combo data in HPV+ malignancies

To read the full story on Seeking Alpha, click here.

PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more PDS Biotechnology Charts.

PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more PDS Biotechnology Charts.

PDS Biotechnology Corporation News

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 24 January 2024 (3 months ago) • Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities
Wednesday 24 January 2024 (3 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Tuesday 23 January 2024 (3 months ago) • Edgar (US Regulatory)

PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer
Tuesday 23 January 2024 (3 months ago) • GlobeNewswire Inc.

PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference
Wednesday 17 January 2024 (3 months ago) • GlobeNewswire Inc.

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Tuesday 5 December 2023 (5 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Tuesday 5 December 2023 (5 months ago) • Edgar (US Regulatory)

PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer
Tuesday 28 November 2023 (5 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Tuesday 28 November 2023 (5 months ago) • Edgar (US Regulatory)

PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update
Tuesday 14 November 2023 (6 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Friday 10 November 2023 (6 months ago) • Edgar (US Regulatory)

PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months
Friday 10 November 2023 (6 months ago) • GlobeNewswire Inc.

More PDS Biotechnology Corporation News Articles

Australian SE All Ordina...

National Australia Bank

Gold vs US Dollar

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions